A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Clinical trial NCT06721013 · RECRUITING

Trial details

NCT number: NCT06721013
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia (ITP)

Start date: 2025-07-30
Primary completion: 2028-05-01
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.